Genmab As Stock Total Asset
| GNMSF Stock | USD 196.00 0.36 0.18% |
Genmab AS fundamentals help investors to digest information that contributes to Genmab A/S's financial success or failures. It also enables traders to predict the movement of Genmab Pink Sheet. The fundamental analysis module provides a way to measure Genmab A/S's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Genmab A/S pink sheet.
Genmab |
Genmab AS Company Total Asset Analysis
Genmab A/S's Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Genmab A/S Total Asset | 24.63 B |
Most of Genmab A/S's fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Genmab AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Based on the latest financial disclosure, Genmab AS has a Total Asset of 24.63 B. This is 227.5% higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. The total asset for all United States stocks is 16.42% higher than that of the company.
Genmab Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Genmab A/S's direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Genmab A/S could also be used in its relative valuation, which is a method of valuing Genmab A/S by comparing valuation metrics of similar companies.Genmab AS is currently under evaluation in total asset category among its peers.
Genmab Fundamentals
| Return On Equity | 0.24 | |||
| Return On Asset | 0.1 | |||
| Profit Margin | 0.47 % | |||
| Operating Margin | 0.38 % | |||
| Current Valuation | 26.41 B | |||
| Shares Outstanding | 65.96 M | |||
| Shares Owned By Institutions | 49.90 % | |||
| Price To Earning | 39.08 X | |||
| Price To Book | 7.94 X | |||
| Price To Sales | 2.45 X | |||
| Revenue | 8.48 B | |||
| Gross Profit | 8.48 B | |||
| EBITDA | 4.24 B | |||
| Net Income | 3.01 B | |||
| Cash And Equivalents | 21.61 B | |||
| Cash Per Share | 330.53 X | |||
| Total Debt | 634 M | |||
| Debt To Equity | 0.03 % | |||
| Current Ratio | 13.11 X | |||
| Book Value Per Share | 408.67 X | |||
| Cash Flow From Operations | 2.23 B | |||
| Earnings Per Share | 12.00 X | |||
| Price To Earnings To Growth | 1.20 X | |||
| Target Price | 383.57 | |||
| Number Of Employees | 1.56 K | |||
| Beta | 0.67 | |||
| Market Capitalization | 26.78 B | |||
| Total Asset | 24.63 B | |||
| Retained Earnings | (3.96 B) | |||
| Working Capital | 3.72 B | |||
| Current Asset | 4.14 B | |||
| Current Liabilities | 419 M | |||
| Z Score | 25.2 | |||
| Net Asset | 24.63 B |
About Genmab A/S Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Genmab AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genmab A/S using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genmab AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| EBR | Centrais Electricas Brasileiras | |
| HE | Hawaiian Electric Industries | |
| VFC | VF Corporation | |
| BVHMF | Vistry Group PLC | |
| S | SentinelOne |
Additional Information and Resources on Investing in Genmab Pink Sheet
When determining whether Genmab A/S offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab A/S's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genmab AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.